Literature DB >> 24738094

Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.

James Q Del Rosso1, Diane Thiboutot, Richard Gallo, Guy Webster, Emil Tanghetti, Lawrence F Eichenfield, Linda Stein-Gold, Diane Berson, Andrea Zaenglein.   

Abstract

The last article in this 5-part series provides a final overview of consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. Optimal management of rosacea requires careful assessment of the patient's clinical features with integration of therapies that adequately treat the presenting signs and symptoms. The treatment consensus recommendations from the AARS are based on 2 major common clinical presentations of rosacea: (1) centrofacial erythema with papulopustular lesions, and (2) centrofacial erythema without papulopustular lesions. The recommendations provided here serve to guide clinicians in their clinical practice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24738094

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  13 in total

1.  Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS).

Authors:  James Q Del Rosso; Emil Tanghetti; Guy Webster; Linda Stein Gold; Diane Thiboutot; Richard L Gallo
Journal:  J Clin Aesthet Dermatol       Date:  2020-06-01

Review 2.  Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2017-09-01

Review 3.  An update on the treatment of rosacea.

Authors:  Alexis Lara Rivero; Margot Whitfeld
Journal:  Aust Prescr       Date:  2018-02-01

Review 4.  Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence.

Authors:  James Q Del Rosso; Emil Tanghetti
Journal:  J Clin Aesthet Dermatol       Date:  2021-03-01

5.  Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions.

Authors:  Terry M Jones; Iain Stuart
Journal:  J Clin Aesthet Dermatol       Date:  2021-03-01

6.  Quality of Life in Individuals with Erythematotelangiectatic and Papulopustular Rosacea: Findings From a Web-based Survey.

Authors:  Joshua A Zeichner; Lawrence F Eichenfield; Steven R Feldman; J Scott Kasteler; Ilia L Ferrusi
Journal:  J Clin Aesthet Dermatol       Date:  2018-02-01

Review 7.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

8.  The Burden of Illness of Erythematotelangiectatic Rosacea and Papulopustular Rosacea: Findings From a Web-based Survey.

Authors:  James Q Del Rosso; Emil A Tanghetti; Hilary E Baldwin; David A Rodriguez; Ilia L Ferrusi
Journal:  J Clin Aesthet Dermatol       Date:  2017-06-01

9.  The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea.

Authors:  Andrew William Johnson; Sandra Marchese Johnson
Journal:  Dermatol Ther (Heidelb)       Date:  2015-06-26

10.  Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.

Authors:  A M Layton; M Schaller; B Homey; M A Hofmann; A P Bewley; P Lehmann; C Nohlgård; D B Sarwer; N Kerrouche; Y M Ma
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-09-28       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.